Applied Genetic Technologies (NASDAQ:AGTC) has been assigned a $8.00 target price by equities research analysts at HC Wainwright in a research report issued on Friday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 102.53% from the stock’s current price.

A number of other equities research analysts have also recently issued reports on AGTC. Wedbush reiterated an “outperform” rating and set a $9.00 target price on shares of Applied Genetic Technologies in a research report on Wednesday, November 8th. Cantor Fitzgerald reiterated a “hold” rating and set a $9.00 target price on shares of Applied Genetic Technologies in a research report on Wednesday, January 17th. Zacks Investment Research cut shares of Applied Genetic Technologies from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 31st. Finally, ValuEngine cut shares of Applied Genetic Technologies from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $10.17.

Shares of Applied Genetic Technologies (NASDAQ AGTC) opened at $3.95 on Friday. The stock has a market cap of $76.90, a PE ratio of -19.75 and a beta of 2.03. Applied Genetic Technologies has a 1 year low of $3.25 and a 1 year high of $8.40.

Applied Genetic Technologies (NASDAQ:AGTC) last announced its earnings results on Friday, February 9th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.20). The firm had revenue of $4.85 million for the quarter, compared to analyst estimates of $8.72 million. Applied Genetic Technologies had a negative return on equity of 2.86% and a negative net margin of 8.78%. The company’s revenue for the quarter was down 55.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.10 EPS. equities research analysts expect that Applied Genetic Technologies will post -1.14 earnings per share for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of AGTC. Virtu KCG Holdings LLC acquired a new stake in Applied Genetic Technologies in the 2nd quarter valued at about $178,000. Dimensional Fund Advisors LP increased its position in Applied Genetic Technologies by 66.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 266,441 shares of the biotechnology company’s stock valued at $1,359,000 after acquiring an additional 106,558 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Applied Genetic Technologies by 1,080.3% in the 2nd quarter. Goldman Sachs Group Inc. now owns 143,606 shares of the biotechnology company’s stock valued at $732,000 after acquiring an additional 131,439 shares in the last quarter. Nine Chapters Capital Management LLC acquired a new stake in Applied Genetic Technologies in the 3rd quarter valued at about $113,000. Finally, ClariVest Asset Management LLC increased its position in Applied Genetic Technologies by 18.5% in the 3rd quarter. ClariVest Asset Management LLC now owns 99,013 shares of the biotechnology company’s stock valued at $391,000 after acquiring an additional 15,491 shares in the last quarter. Hedge funds and other institutional investors own 46.59% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://theolympiareport.com/2018/02/11/applied-genetic-technologies-agtc-pt-set-at-8-00-by-hc-wainwright.html.

Applied Genetic Technologies Company Profile

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

Analyst Recommendations for Applied Genetic Technologies (NASDAQ:AGTC)

Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.